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Abstract Advanced glycation endproducts have been
implicated in the development of diabetic complications. In
addition, these products could also mediate certain bone
alterations such as diabetic osteopenia. Several receptors
specific for advanced glycation endproduct-modified pro-
teins have been characterized in different cell types, con-
tributing to the recognition and degradation of senescent pro-
teins. In the present report, we investigated the possible pres-
ence of advanced glycation endproduct-binding proteins on
osteoblast-like cells. Both UMR106 and MC3T3E1 cell lines
express specific advanced glycation endproduct-binding
sites, with an affinity constant between 0.4 and 1.7 • 106 M-1,
depending on the stage of osteoblastic differentiation; and
with a receptor capacity of 1.5-2.0 • 107 sites/cell. Osteoblast-
like cells were also found to participate both in the uptake
and degradation of advanced glycation endproduct-modified
bovine serum albumin at 37ºC. Radiolabelled ligand blotting
studies confirmed the presence of several membrane binding
proteins, with apparent molecular masses of 50, 45-40, 30,
25 and 18 kDa; the major bands corresponded to 30 and 25
kDa proteins. This study provides evidence of the presence
of advanced glycation endproduct-specific binding sites, and
for their regulation with the stage of differentiation, in two
osteoblast-like cells in culture.
Key words Non-enzymatic glycosylation • Advanced glyca-
tion endproducts • Receptor for advanced glycation endprod-
ucts • Diabetes mellitus • Osteoblasts • Bone • Osteopenia
A.D. McCarthy • S.B. Etcheverry • A.M. Cortizo
Advanced glycation endproduct-specific receptors in rat and mouse
osteoblast-like cells: regulation with stages of differentiation
Received: 24 August 1998 / Accepted in revised form: 24 February 1999
O R I G I N A L
A.D. McCarthy • S.B. Etcheverry • A.M. Cortizo (Y)
Cátedra de Bioquímica Patológica,
Facultad de Ciencias Exactas,
Universidad Nacional de La Plata,
Calle 47 y 115, RA-1900, La Plata, Argentina
Acta Diabetol (1999) 36:45-52 © Springer-Verlag 1999
Introduction
In poorly controlled diabetes mellitus, excessive non-enzy-
matic glycosylation (glycation) of proteins, lipids and nucle-
ic acids occurs as a consequence of hyperglycaemia. During
this process, a reducing sugar such as glucose initially reacts
reversibly with a free amino group, resulting in the formation
of a Schiff base. An intramolecular rearrangement then gives
rise to a more stable, but still freely reversible, molecule: the
Amadori product. With time, Amadori products can irre-
versibly progress to the formation of a family of cross-linked
and fluorescent compounds, collectively known as advanced
glycation endproducts (AGEs) [1, 2]. Since the formation of
AGEs is essentially irreversible, they continue to accumulate
over the years, particularly in long-lived structural proteins
of insulin-independent tissues [3, 4].
Evidence has accumulated suggesting that AGEs could
be involved in the pathogenesis of ageing and atherosclero-
sis, as well as in the appearance and progression of diabetic
microangiopathies (nephropathy, retinopathy and neuropa-
thy) [5]. Most studies have demonstrated that AGEs can
induce structural and functional alterations of several pro-
teins. In addition, incubation with protein-AGEs has been
shown to elicit various modifications in the normal physiol-
ogy of different tissues and cells in culture, the mechanisms
of which are not fully understood. Similarly, high levels of
AGEs have been found in the serum of diabetic and non-dia-
betic patients with end-stage renal disease, especially in
association with peptides smaller than 10 kDa [6], which
have been termed “second generation” AGEs. These highly
reactive peptides have been implicated in the pathogenesis
of haemodialysis-associated amyloidosis, through sec-
ondary AGE-modification of β-2 microglobulin [7].
Cell-surface receptors or binding proteins specific for
AGE moieties have been detected on circulating mono-
cyte/macrophages [8] and T-lymphocytes [9], and on
endothelial cells [10], mesangial cells [11] and other cell
types. These proteins, with or without receptor characteris-
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tics, appear to contribute to diverse cellular functions
(chemotaxis, adhesion, activation, cell growth and differ-
entiation), as well as to the specific recognition and degra-
dation of AGE-modified proteins, clotting and barrier func-
tion [1]. Several AGE-receptors have been characterized,
such as p60 (OST-48) [12], p90 (80 K-H) [12], the
macrophage scavenger receptor [13], a 35 kDa member of
the immunoglobulin superfamily of receptors (RAGE) [14,
15], galectin-3 (a 32 kDa protein also known as Mac-2)
[16], and a novel receptor that mediates AGE-induced
chemotaxis in rabbit smooth muscle cells [17].
Several studies, both in vivo and in vitro, have suggest-
ed that AGEs could mediate bone alterations, such as
osteopenia, which occur in poorly controlled diabetic
patients. Recently, AGE-modified collagen has been
detected in the cortical bone of diabetic and ageing rats
[18-20]. In addition, Fong et al. [21] found that the forma-
tion of AGE on bone matrix diminishes its ability to induce
bone formation. AGE-modified proteins have also been
shown to enhance osteoclast-induced bone resorption [22],
to stimulate interleukin-6 (IL-6) production by human
bone-derived cells [23] and to dose-dependently inhibit the
phenotypic expression of a primary culture of rat
osteoblasts [20]. In addition, our group has demonstrated
that AGE-modified proteins regulate the growth of mouse
MC3T3E1 and rat UMR106 osteoblastic cells: an increase
in cell proliferation and differentiation was observed after
short incubation periods, while long-term cultures with
protein-AGEs induced a depression in both parameters
[24]. Our results suggested that AGEs directly regulate
osteoblast growth. However, the mechanisms by which
AGEs would regulate this growth were not studied.
In the present report, we investigated the possible pres-
ence of AGE-binding proteins on UMR106 and MC3T3E1
osteoblastic cells. We also compared the kinetic parameters
and molecular masses of these receptors with others which
have been previously described in different cell types, as
well as their regulation throughout the different stages of
osteoblastic differentiation.
Materials and methods
Materials
Bovine serum albumin (BSA), phenyl-methyl-sulphonyl-fluoride
(PMSF), p-nitro-phenyl-phosphate (pNPP), glucose 6-phosphate
(G6P), Iodo-Gen, tri-chloro-acetic acid (TCA), Triton X-100,
prestained molecular weight standards, Kodak XAR-5 photo-
graphic film, Sephadex G-25 and G-50 were purchased from
Sigma (St. Louis, MO., USA). Dulbecco’s modified Eagle’s
medium (DMEM), RPMI-1640 and trypsin/EDTA were from
Gibco (Life Technologies, Grand Island, N.Y., USA). Fetal
bovine serum (FBS) was purchased from Gen (Buenos Aires,
Argentina). Centricon 10 kDa cut-off filter cartridges were from
Amicon Inc. (Beverly, Mass., USA). 125I was from New England
Nuclear. All other chemicals were of analytical grade.
Preparation of AGE-protein
AGE-BSA was prepared as we have previously described [24].
Briefly, BSA was incubated under sterile conditions in 150
mmol/L phosphate-buffered-saline (PBS), pH 7.4, with 100
mmol/L G6P at 37ºC for 6 weeks in the presence of protease
inhibitors (1.5 mmol/L PMSF) and antibiotics (100 U/ml peni-
cillin, 100 mg/l streptomycin). Control BSA was incubated under
the same conditions without G6P. At the end of the incubation
period, BSA and AGE-BSA were separated from non-covalently
bound low molecular weight molecules by centrifugation/filtra-
tion with Centricon filter cartridges. The formation of AGE pro-
teins was assessed by their characteristic fluorescence-emission
maximum at 420 nm upon excitation at 340 nm, using an Aminco-
Bowman SPF100 spectrofluorometer equipped with an off-axis
Ellipsoidal Mirror Condensing System and an Aminco Ratio
Photometer. The excitation source was an 150W Xenon arc lamp
and the detector was an RCA 4837 photomultiplier tube. Standard
1 x 1 cm quartz cells were used and spectra were recorded on a
Linseis 1600 x-y recorder. Quinine (1 µg/ml) was used as a fluo-
rescence intensity standard to calibrate and monitor the perfor-
mance of the fluorescence spectrophotometer. Fluorescence val-
ues of test substances were expressed as percentage relative fluo-
rescence. Thus, the estimated level of AGE-BSA obtained in this
in vitro incubation was 17.6% relative fluorescence intensity/mg
protein, as opposed to 2.2% for control BSA.
Cell culture
UMR106 rat osteosarcoma-derived cells were grown in 75 cm2
plastic flasks at 37ºC in a humidified 5% CO2 atmosphere in
DMEM supplemented with 10% FBS, 100 U/ml penicillin and
100 mg/l streptomycin. This cell line has been shown to conserve
certain characteristics of differentiated osteoblastic phenotype
[25]. After 5-7 days, cells were sub-cultured using trypsin/EDTA
and replated to begin the experiments. Cells were split at subcon-
fluence and plated in 48-well plates (2.5 • 104 cells/well) in 10%
FBS-DMEM. Subconfluent cells were then serum deprived, and
washed with RPMI-1640 before being submitted to the studies
described below.
MC3T3E1 osteoblastic mouse calvaria-derived cells were
grown in DMEM-10% FBS and antibiotics, and passaged every 4-6
days. Previous studies have demonstrated that expression of
osteoblastic markers begins after culturing these cells for 10 days
with medium supplemented by 5mmol/L β-glycerol-phosphate
and 25 mg/L ascorbic acid. In addition, mineralization is achieved
with these cells after extending this culture to 20 days. However,
the cells only undergo active replication during the first 10 days
of incubation [26]. Thus, in order to study the expression of AGE-
receptors in the above stages of this cell line, different protocols
were chosen. To obtain cells in active proliferation, cells were
plated in 48-well plates (2.0 • 104 cells/well) and cultured for 3
days in DMEM-10% FBS. In other experiments, MC3T3E1 cells
were plated in 48-well plates (2.0 • 104 cells/well), and cultured
in 10% FBS-DMEM supplemented with 5 mmol/L β-glycerol-
phosphate and 25 mg/l ascorbic acid for either 15 days (differen-
tiated cells) or 25 days (mineralizing cells), changing the medium
every 2 days. At the end of all incubations, cells were serum
deprived, washed with RPMI-1640, and submitted to receptor
binding studies as described below.
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Alkaline phosphatase (ALP) determination
The cell monolayer from individual wells was solubilized in 0.5 ml
0.1% Triton X-100. Aliquots of total cell extract were then saved for
protein determination using the Bradford method [27], and for mea-
surement of the osteoblastic differentiation marker ALP as we have
described previously [24].
Radiolabelling of AGE-BSA
AGE-BSA was iodinated with carrier-free 125I by the Iodo-Gen
method of Fraker and Speck [28]. Briefly, 30 µg of AGE-BSA in PBS
was incubated with 0.5 mCi carrier-free 125I in an Iodo-Gen-coated
vial at room temperature for 20 min. To separate free from bound 125I,
the sample was fractionated by Sephadex G-25 column chromatog-
raphy, and the fraction corresponding to 125I-AGE-BSA was further
purified by a Sephadex G-50 50 ml column, until more than 98%
radioactivity was TCA precipitable. Protein concentrations were
determined by the method of Bradford [27], using BSA as a standard.
Specific radioactivity of labelled 125I-AGE-BSA was between 1.1 •
104 and 1.8 • 104 cpm/ng protein.
Determination of protein/cell count standard curves
Standard curves were determined to evaluate the correlation between
cell number and total protein content, for both UMR106 and
MC3T3E1 cells. Briefly, confluent cells growing in a 75 cm2 flask
were trypsinized and seeded in serial dilutions in 24-well plates (8.0,
4.0, 2.0, and 1.0 • 104 cells/well, each condition in triplicate). They
were then cultured in 10% FBS-DMEM for 48 h, at 37ºC and in a
humidified 5% CO2 atmosphere. Finally, individual wells were either
trypsinized (for cell count determination with a haemocytometer), or
washed with PBS and solubilized with 0.1% Triton X-100 for protein
determination by the method of Bradford [27]. Cell count as com-
pared to protein content was then evaluated by linear regression
analysis for both MC3T3E1 osteoblasts (r = 0.991, p < 0.001) and
UMR106 osteosarcoma cells (r = 0.997, p < 0.001).
Whole-cell homogenate and membrane preparation
Sub-confluent UMR106 or MC3T3E1 cells in active replication
growing in 75 cm2 flasks were washed with PBS, scraped, taken up
in PBS and spun at 1000 • g for 5 min. The supernatant was discard-
ed, and the cellular pellet was solubilized in 0.1% Triton X-100.
Bradford’s method was used to determine protein concentration [27].
This whole-cell homogenate was saved for ligand blot studies as
described below. In other experiments, osteoblast-like cells were
grown to confluency in 150 cm2 flasks. Cells were washed with PBS,
resuspended in a homogenizing buffer (25 mmol/L Tris, 250 mmol/L
sucrose, 2 mmol/L EDTA, 5 mmol/L β-mercapto ethanol, 1 mmol/L
PMSF, pH 7.4), and sonicated three times at 60 psi for 15 s. The
homogenate was centrifuged at 1 000 • g for 10 min, and the super-
natant was further centrifuged at 10 000 • g/4°C for 30 min.
Membranes were then isolated from the supernatant by centrifuga-
tion at 105 000 x g for 60 min at 4°C. The resulting pellet was solu-
bilized in 0.1% Triton X-100/PBS. Protein concentration was deter-
mined by the method of Bradford [27]. This material was then used
for ligand blotting.
Binding studies
Radioligand binding studies were carried out with UMR106 and
MC3T3E1 cells, cultured on 48-well plates under the conditions
described above. These displacement studies were performed in 0.25
ml binding medium (RPMI-1640, 25 mmol/L Hepes, pH 7.4, 5 g/l
BSA) at 4ºC, as previously described [9]. Cell monolayers were pre-
incubated for 30 min with increasing concentrations of unlabelled
AGE-BSA (0-1000 µg protein/ml binding medium), following which
106 cpm of 125I-AGE-BSA was added to each well. These doses were
chosen since the activity of AGE-products on the differentiation and
proliferation of these cell lines occurs between 100 and 1 000 µg pro-
tein/ml incubation medium, as we have described previously [24].
After incubating for 2 h at 4°C, the supernatant was aspirated and the
cell layers were washed three times each with cold PBS/0.5% BSA,
and cold PBS alone. Cell monolayers were then solubilized in 0.5 ml
0.1% Triton X-100, which was transferred to tubes for counting in a
Hewlett Packard PRIAS gamma counter, and for protein determina-
tion according to the method of Bradford [27]. Non-specific binding
of 125I-AGE-BSA was determined in parallel incubations by adding
an excess of unlabelled AGE-BSA. Specific binding was defined as
the difference between total binding (cells incubated with radioligand
and a known amount of unlabelled AGE-BSA) and non-specific
binding (as defined above). 125I-AGE-BSA was also co-incubated
with an excess of control BSA. Protein concentrations were used to
estimate cell number through the standard curves described above. At
least three experiments were run for each experimental condition.
Uptake and degradation
Osteoblast-like cells were grown to confluency in 24-well plates in
DMEM-10% FBS. Cells were washed with RPMI-1640 and incu-
bated at 37°C for different periods of time with RPMI-1640/0.5%
BSA/125I-AGE-BSA, with or without an excess of unlabelled AGE-
BSA. After these incubations, medium was taken up from each well,
and degraded 125I-AGE-BSA was determined by measuring TCA-
non-precipitable radioactivity [9]. The remaining cell monolayers
were washed as for binding experiments. Cells were then solubilized
with 0.5ml 0.1% Triton X-100, and cell-associated radioactivity was
determined. Specific uptake was defined by the same criteria as used
for the binding studies.
Ligand blotting
In order to perform ligand blot studies for cellular AGE-binding pro-
teins, UMR106 or MC3T3E1 whole-cell homogenates or membrane
preparations (100 µg protein aliquots) were resuspended in 2 x
Laemmli’s sample buffer [29] containing β-mercapto ethanol and
boiled for 3 min. Samples were electrophoresed on 12% SDS-PAGE,
with prestained molecular weight standards processed in parallel.
Overnight electroblotting onto a nitrocellulose filter was performed.
After blocking for 2 h with a cold solution of PBS containing 1%
BSA and 0.1% Triton X-100, the nitrocellulose filter was probed at
4ºC for 2 h with 125I-AGE-BSA alone, or co-incubated with 1 000
µg/ml of either BSA or unlabelled AGE-BSA. The blot was washed
twice with blocking solution, and then three times with PBS. After air
drying, it was exposed to Kodak XAR-5 film at -70ºC, for autoradi-
ographic evaluation [11].
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Statistical analysis
Scatchard analysis [30] of the raw data from binding experiments
was performed, in order to estimate receptor number and binding
affinity constant, and to determine the standard error.
Results
125I-AGE-BSA binding to osteoblast-like cells
Radioligand binding experiments were performed by incubat-
ing either UMR106 or MC3T3E1 cells with 125I-AGE-BSA at
4°C for 2 h. Cell-associated 125I-AGE-BSA was found to
increase dose-dependently (Fig. 1). This binding was inhibit-
ed by an excess of unlabelled AGE-BSA, but not by control
BSA. For instance, in the case of proliferating MC3T3E1
cells, the maximal binding was 0.86 % ± 0.07 % B/T per 100
µg protein; 0.25 % ± 0.03 % B/T per 100 µg protein in the
presence of excess AGE-BSA; and 0.84 % ± 0.07 % B/T per
100 µg protein, with an excess of control BSA. Specific bind-
ing, as defined in Methods, is represented in Fig. 1 and shows
a saturation pattern. Scatchard analysis of these specific bind-
ing data show results which are compatible with a one-site
binding system (see inserts in Fig. 1).
It was apparent from the Scatchard analysis that
MC3T3E1 cells, at the proliferative stage, showed a higher
affinity of the receptor for 125I-AGE-BSA when compared
with the osteosarcoma line UMR106. However, no differ-
ences were found in receptor number, and both cell types
showed a similar capacity for AGE binding to receptors (Table
1). These results suggested a relationship between AGE bind-
ing and the stage of osteoblastic differentiation. To further
investigate this hypothesis, we studied the regulation of AGE
receptors on MC3T3E1 osteoblast-like cells after induction of
their differentiation by ascorbic acid/β-glycerol phosphate
incubation, as described in Materials and methods. Cellular
levels of ALP were determined to establish these stages of dif-
ferentiation [26]. After culture for 72 h, the cells in the prolif-
erative stage expressed undetectable levels of ALP. This mark-
er was significantly higher after 15 days culture (ALP = 2.2
µmol pNP per min-1 per g protein-1), which corresponds to the
cells’ differentiated stage. Furthermore, cell-associated specif-
ic activity of ALP reached a plateau after 25 days of culture
(ALP = 8.5 µmol pNP per min-1 per g protein-1) coinciding
with the osteoblasts’ mineralizing stage. 125I-AGE-BSA bind-
ing was then investigated in each case, and the kinetic para-
meters found are shown in Table 1. These results indicate a
decrease in specific binding as the MC3T3E1 cells become
more differentiated. These changes can be accounted for by
the observed decrease in the affinity constant, since no
changes in the density of cellular receptors was found.
AGE-protein uptake and degradation
To assess whether osteoblast-like cells can internalize and
degrade AGE proteins, cells were incubated with 125I-AGE-
Fig. 1A, B Saturability of AGE-BSA binding to UMR106 (A) and proliferating MC3T3E1 (B) osteoblast-like cells. Specific binding ver-
sus the concentration of AGE-BSA is plotted. The figure shown corresponds to the mean ± SEM for three independent experiments, each
performed by sextuplicate. Data were analysed by a non-linear least squares programme and the curve indicates the best fit line. Insert,
Scatchard analysis of the binding data. Data from binding experiments were fit to the equilibrium binding equation B = nKA/(1+KA),
where B is the amount of specifically bound ligand, n is the number of binding sites per cell, A is the concentration of free radioligand,
and K is the association constant
A B
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BSA at 37°C for different periods of time. In the case of
MC3T3E1 osteoblasts, specific cell-associated AGE-BSA
was found to accumulate in a time-dependent manner
throughout the 24 h incubation period (Fig. 2A). In addition to
this 125I-AGE-BSA uptake, TCA-soluble radioactivity derived
from AGE-protein degradation was detected in the medium,
and increased with incubation time up to 24 h (Fig. 2B). On
the other hand, 125I-AGE-BSA uptake and degradation by
UMR106 cells up to 24 h exhibited both faster kinetics and a
saturable pattern (Fig. 2A and B). In absolute terms, these two
osteoblast-like cell lines attain a similar 125I-AGE-BSA spe-
cific uptake after 24 h of culture, although more AGE-protein
appears to be degraded by the osteosarcoma UMR106 line
than by MC3T3E1 cells in the same period of time (Fig. 2B).
Ligand blot
To confirm and further characterize the presence of AGE
binding sites on osteoblast-like cells, ligand blotting stud-
ies were carried out under reducing conditions using either
whole cell homogenates or extracts of osteoblastic cell
membranes. As shown in Fig. 3A, two AGE-binding pro-
teins were observed in the homogenates of UMR106 and
MC3T3E1 osteoblast-like cells, with apparent molecular
masses of ~ 45 kDa (minor band) and 30 kDa (major
band). However, cell membrane preparations showed sev-
eral AGE-binding proteins: two major bands with apparent
molecular masses of 30 and 25 kDa, and minor bands with
molecular masses of 50, 40-45 and 18 kDa (Fig. 3B). The
binding of 125I-AGE-BSA to these sites, both in whole-cell
homogenates and in membrane preparations, was specifi-
cally blocked by 1 000 µg/ml of unlabelled AGE-BSA (Fig.
3A and B, lanes 3 and 4). However, in the presence of an
excess of control BSA, two bands of 45 and 30 kDa were
observed with whole-cell extracts, showing similar inten-
sity to those described above. Similar patterns of 125I-
AGE-BSA binding proteins were obtained for both
UMR106 and MC3T3E1 osteoblastic lines (Fig. 3A and B,
lanes 1 and 2).
Table 1 Kinetic parameters resulting from the Scatchard analysis of binding data of AGE-BSA to osteoblast-like cells. Data represent the
mean of at least three independent experiments
Cell type Stage of differentiation Ka [M-1] Ro [sites/cell]
UMR106 0.4 ± 0.1 . 106 2.0 ± 1.2 . 107
MC3T3E1 Proliferative 1.7 ± 0.8 . 106 1.5 ± 0.9 . 107
MC3T3E1 Differentiated 1.4 ± 0.5 . 106 1.5 ± 0.8 . 07
MC3T3E1 Mineralizing 0.6 ± 0.1 . 106 1.8 ± 0.5 . 107
A B
Fig. 2A, B Time-dependent AGE-specific uptake (A) and degradation (B) of 125I-AGE-BSA by UMR106 (P) and MC3T3E1 (K)
osteoblast-like cells. Data represent the mean ± SEM of two independent experiments, each performed in triplicate
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Discussion
Advanced glycation endproducts have been implicated in the
development of chronic complications of diabetes, such as
nephropathy, retinopathy, neuropathy and macrovascular dis-
ease [1]. In addition, several lines of evidence have recently
suggested that AGEs could also contribute to the osteopenia
found in poorly compensated patients with type 1 diabetes.
AGE-modified collagen has been shown to accumulate in the
bones of diabetic rats, in relation to the duration of diabetes
[18-20]. AGEs have also been found to enhance osteoclast-
induced bone resorption [22], and to inhibit the phenotypic
expression both of a primary culture of rat osteoblasts, and of
MC3T3E1 and UMR106 osteoblast-like cell lines [20, 24].
Furthermore, AGEs have been shown to enhance the produc-
tion of potent bone-resorption factor IL-6 in normal human
bone-derived cells [23]. These results point towards a role for
AGE-modified proteins in the regulation of osteoblast and/or
osteoclast differentiation. However, the mechanisms by which
AGE would exert these effects remain poorly defined.
Recent evidence has documented the existence of a family
of AGE receptors/binding proteins, with different molecular
masses and cellular functions [1]. Our present study indicates
that both UMR106 and MC3T3E1 osteoblastic cells express
binding sites which specifically recognize glucose-modified
proteins. The evidence supporting the presence of AGE-recep-
tors in these cells includes several findings. Both osteoblastic
cell lines are able to bind AGE-BSA in a saturable manner,
showing half-maximal binding between 35-120 µg AGE-
BSA/ml. In addition, these cells show an affinity for AGE-BSA
which is comparable to that of mesangial cells (2.0 • 106 M-1)
[11], but an order of magnitude lower than that reported for
other systems such as macrophage/monocytes, endothelial
cells, T-lymphocytes and smooth muscle cells (1.0-7.8 • 107
M-1) [8-10, 17]. However, the number of AGE molecules
bound per osteoblastic cell ranges between 1.5 • 107 and 2.0 •
107, which is one or two orders of magnitude greater than the
cellular density reported for other cells [8-10, 17].
The kinetic parameters of the AGE-receptors described in
this study suggest that osteoblastic cells could respond to
AGE-modified proteins through these receptors. As we have
previously described, the effects of AGE-BSA on osteoblastic
proliferation and differentiation [24] are dose-dependent,
being half-maximal at 50-200 µg/ml. This concentration range
is approximately equal to the AGE-BSA doses needed for
half-maximal binding to cell surface binding sites. Thus, at the
concentration range where AGE-BSA exerts its bioactivity on
osteoblast-like cells, its specific binding sites are significantly
occupied and could mediate the previously described effects.
However, direct evidence to prove this hypothesis deserves
further studies using anti-receptor antibodies.
In recent studies, Tomasek et al. [18] showed that colla-
gen-linked fluorescence was significantly increased in the cor-
tical bone of diabetic rats (28.0 ± 2.7 in diabetic vs 15.3% ±
1.9% in control rats, expressed as a percentage of relative flu-
orescence per mg collagen). An increase in fluorescence was
A B
Fig. 3A, B Ligand blotting of 125I-AGE-BSA to either whole-cell extracts (A) or membrane fractions (B) in the presence or absence of an
excess of unlabelled AGE-BSA. In both cases, samples obtained from UMR106 cells (lanes 1 and 3) and MC3T3E1 cells (lanes 2 and 4)
were processed in a similar manner. Samples were subjected to SDS-PAGE, followed by overnight electroblotting onto nitrocellulose
membranes and incubated with 125I-AGE-BSA as a probe (2 • 106 cpm/ml incubation medium; 1.5 • 104 cpm/ng protein). Specific binding
was determined in the presence of 0 or 1 000 µg/ml of unlabelled AGE-BSA, using autoradiographic detection. Pre-stained molecular
weight markers were run in parallel lanes
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also found to correlate with ageing (2.05-fold for 30-
month-old vs 3-month-old rats). In addition, Katayama et
al. [20] demonstrated that in streptozotocin-induced diabet-
ic rats 8 weeks post-injection, fluorescent AGEs bound to
collagen (obtained from the tibiae) increased significantly,
reaching a level of about 20% relative fluorescence/mg col-
lagen, compared to 8% in control rats. The levels of AGE
formed on BSA in our system, as assessed by fluorescence
analysis, are thus similar to those found in collagen
obtained from bone samples of diabetic rats [18, 20]. The
previous and present studies suggest that AGE-formation
on several proteins may contribute to alterations observed
in the bones of uncompensated diabetic patients.
In further experiments, ligand blot analysis confirmed
the presence of several membrane proteins that bind 125I-
AGE-BSA, with apparent molecular masses of 50, 45-40,
30, 25 and 18 kDa. The binding of labelled AGE-BSA,
either to osteoblast monolayers or to blotted membrane
proteins, is specific for AGE-modified proteins, since no
displacement was found in any case with an excess of
unmodified BSA.
The major AGE binding site described in the present
study, (30 kDa binding protein), may be structurally simi-
lar either to galectin-3, a 32 kDa AGE-receptor [16]; or to
RAGE, the 35-kDa AGE-binding protein isolated from
bovine lung [15]. In this context, it is interesting to note
that RT-PCR analysis of total RNA extract from a primary
culture of human bone-derived cells has demonstrated their
expression of mRNA specific for RAGE [23]. On the other
hand, 125I-AGE-BSA ligand blotting of liver cell plasma
membranes under reducing conditions has shown a pattern
of binding proteins which is similar to our present results
for osteoblastic cells [31]. In this latter study, the authors
identified AGE-receptors p60 and p90 as OST-48 and 80
K-H proteins, respectively. Accordingly, several molecules
capable of recognizing AGE-modified proteins could be
present in osteoblast-like cell membranes.
The present study shows evidence for a differential reg-
ulation of AGE-receptors according to the stage of
osteoblastic differentiation. UMR106, an established
osteosarcoma cell line, expresses several markers of
osteoblastic phenotype, namely bone-specific alkaline
phosphatase, type I collagen synthesis and PTH-inducible
cAMP levels [25]. In our experiments, we have found these
cells to express AGE-receptors with a relatively low affin-
ity for AGE-modified proteins. In comparison, MC3T3E1
cells in active proliferation show binding sites with a simi-
lar capacity but higher affinity for AGEs. However, prolif-
erating MC3T3E1 cells have been reported to differentiate
into osteoblastic cells morphologically and functionally,
when they are cultured in a medium supplemented with β-
glycerol-phosphate and ascorbic acid [26]. By using this
model of sequential osteoblastic proliferation, differentia-
tion and mineralization, we have found that the affinity of
AGE-binding sites decreases with an increase in cellular
differentiation (as assessed by their expression of
osteoblast marker ALP). These results show for the first
time a regulation of AGE-receptors with the stage of
osteoblastic differentiation.
Similarly, in lung tissue cellular expression of RAGE
has been associated with a mature phenotype. Katsuoka et
al. [32] have shown that the presence of RAGE-mRNA
correlates with an alveolar phenotype in lung cells, sug-
gesting a role for these receptors in specific cellular func-
tions. In addition, expression of RAGE (both mRNA and
protein) was shown to be strongly reduced or absent in
non-small-cell lung carcinoma, as opposed to normal lung
tissue [33]. These investigators have suggested that the
down-regulation of RAGE could be involved in lung
tumour formation.
In addition to their ability to bind AGE-BSA,
osteoblast-like cells also participate both in the uptake and
degradation of AGE-BSA at 37°C. These cells specifically
accumulate and slowly degrade 125I-AGE-BSA, with kinet-
ics which follow closely those of AGE-BSA uptake in each
osteoblastic cell line. That osteoblast-like cells can bind,
internalize and degrade AGE-modified proteins, suggests a
role for their AGE-receptors in the turnover of bone and
extracellular matrix proteins. A recent study has provided
in vitro and in vivo evidence of AGE-protein enhanced
bone resorption [22]. The effect of AGE-proteins obtained
in vitro on the number of resorption pits formed on dentin
slices was observed at 1 µmol/L AGE-protein concentra-
tion. These authors thus postulate the participation of
AGEs in the remodelling of senescent bone matrix tissues,
although the mechanisms by which AGEs enhance osteo-
clast-induced bone resorption were not investigated in their
study. However, AGE-induced bone resorption, if it does
occur physiologically, could also be partly accounted for
by the AGE-dependent secretion of IL-6, which has been
described for human bone-derived cells [23]. Moreover,
these effects are in general agreement with our previous
findings in osteoblastic cell lines, in which relatively long-
term incubation with AGE-protein concentrations of 1.7-17
µmol/L inhibited cellular growth [24]. Thus, the presence
of AGE-receptors on osteoblastic cells could contribute, at
least in part, to the turnover of senescent bone and matrix
proteins, which accumulate physiologically in ageing indi-
viduals, and at an increased rate in pathological situations
such as diabetes.
In summary, this study has provided evidence for the
presence of AGE-specific binding sites, and for their regu-
lation with the stage of differentiation, in two osteoblast-
like cells in culture.
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